|Bid||0.00 x 900|
|Ask||231.62 x 900|
|Day's Range||229.35 - 231.74|
|52 Week Range||128.52 - 237.47|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||110.10|
|Earnings Date||Jul. 20, 2021 - Jul. 26, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||256.32|
IQVIA (IQV) could produce exceptional returns because of its solid growth attributes.
IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.
Global spending on medicines — using invoice price levels — is expected to grow at 3-6 percent CAGR through 2025 to reach about $1.6 trillion by 2025, excluding spending of COVID-19 vaccines, according to a new research report The Global Spending and Usage of Medicines released by the IQVIA™ Institute for Human Data Science. The total cumulative spending on COVID-19 vaccines through 2025 is projected to be $157 billion, largely focused on the initial wave of vaccinations to be completed by 2022. In subsequent years, booster shots are expected to be required on a biannual basis as the durability of immunity and the continued emergence of viral variants make an endemic virus the most likely outcome.